Investment firms attending the 22nd Anglonordic Lifescience Conference

120 Capital/6 Dimensions Capital, 4BIO Capital, Advent Life Sciences, AION Labs, Albion VC, ALSA Ventures, Angel Investor, ARCH Venture Partners, Astellas, Axilium Holding AB, BGF Biovision Ventures, BlackRock (Kreos Capital), BNP Paribas Asset Management, Brandon Capital, British Business Bank, Calculus Capital, Caldwell Capital, Cambridge Technology Capital, Cell and Gene Therapy Catapult (Ventures), Claret Capital Partners, Consensus Business Group, CPI Enterprises, Deepbridge Capital, Epidarex Capital, Eppendorf Group SE & Co. KG. Evolutia Venture Partners, Flerie Invest AB, Forbion, Foresight Group, Future Planet Capital, GL Capital, Gliding Ant Ventures, Global Brain, Gold Nest Capital, Great Stuff Ventures, Hermes Partners Intl., H Tree Capital, ICG, Illumina Ventures, Inveready Asset Management, JJDC, Kerna Ventures, Kineo Finance, LongRiver Investments, Longwall Venture Partners, M Ventures, Maudsley Enterprise, Mazeation, Medicines Discovery Catapult, Meltwind, Mid Atlantic Bio Angels, MSD, Momentum Biotech, New Science Fund, NG Bio Ltd, Nodenza Venture Partners, Novateur Ventures, o2h Ventures, Octopus Ventures, OMX Ventures, OrbiMed, OSE, Otsuka Pharmaceutical, Panacea Capital, Panmure Liberum Cambridge Capital, Parkinson's UK Virtual Biotech, Peppermint VenturePartners, Polar Capital, Rosetta Capital, RYSE, SCI Ventures, Sofinnova Partners, Sound Bioventures, SPRIM Global Investments, Sunstone Life Science Ventures, Syncona Partners, The Pioneer Group, UKI2S, Vesalius Biocapital, XGEN Venture, Zinc.
(86 correct at 2 April 2026).